June 22, 2020

Much is pleased to announce that David Clough and Christopher Cabral have joined the firm as principals in the Intellectual Property & Technology group. Both attorneys focus their practices on protecting the intellectual property of biotechnology, pharmaceutical and chemical companies.

As a lawyer, litigator and scientist, David collaborates with clients on designing and implementing global IP strategies. Businesses frequently turn to him for IP due diligence analysis in multibillion-dollar acquisitions. He represents clients before courts and administrative agencies and in private mediation and arbitration. He also guides clients through re-examination proceedings and European oppositions.

Chris counsels clients in all aspects of patent prosecution and patent counseling, including opinion work specific to freedom to operate, invalidity, non-infringement, patentability and industry landscape analyses. Chris has developed patent portfolios for several developmental stage biologics and counsels clients on patent term extensions, adjustments and FDA exclusivity.

David earned his J.D. from Chicago-Kent College of Law, his Ph.D. from Medical College of Wisconsin and his B.S. from University of Arizona. Chris earned his J.D. from Northwestern Pritzker School of Law, his Ph.D. from Baylor College of Medicine and his B.S. from University of Houston.

This article contains material of general interest and should not be construed as legal advice or a legal opinion on any specific facts or circumstances. Under applicable rules of professional conduct, this content may be regarded as attorney advertising.